Display options
Cite
Tura A, Farngren J, Schweizer A, et al. Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin. Int J Endocrinol. 2015;2015:484231doi: 10.1155/2015/484231.
Tura, A., Farngren, J., Schweizer, A., Foley, J. E., Pacini, G., & Ahrén, B. (2015). Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin. International journal of endocrinology, 2015484231. https://doi.org/10.1155/2015/484231
Tura, Andrea, et al. "Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin." International journal of endocrinology vol. 2015 (2015): 484231. doi: https://doi.org/10.1155/2015/484231
Tura A, Farngren J, Schweizer A, Foley JE, Pacini G, Ahrén B. Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin. Int J Endocrinol. 2015;2015:484231. doi: 10.1155/2015/484231. Epub 2015 Oct 26. PMID: 26587020; PMCID: PMC4637474.
Copy Download .nbib Format: NLM
Share it on

Int J Endocrinol. 2015;2015:484231. doi: 10.1155/2015/484231. Epub 2015 Oct 26.

Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin.

International journal of endocrinology

Andrea Tura, Johan Farngren, Anja Schweizer, James E Foley, Giovanni Pacini, Bo Ahrén

Affiliations

  1. CNR Institute of Neuroscience, Corso Stati Uniti 4, 35127 Padova, Italy.
  2. Department of Clinical Sciences, Lund University, B11 BMC, 22184 Lund, Sweden.
  3. Novartis Pharma AG, 4002 Basel, Switzerland.
  4. Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936, USA.

PMID: 26587020 PMCID: PMC4637474 DOI: 10.1155/2015/484231

Abstract

The study explored the utility of four-point preprandial glucose self-monitoring to calculate several indices of glycemic control and variability in a study adding the DPP-4 inhibitor vildagliptin to ongoing insulin therapy. This analysis utilized data from a double-blind, randomized, placebo-controlled crossover study in 29 patients with type 2 diabetes treated with vildagliptin or placebo on top of stable insulin dose. During two 4-week treatment periods, self-monitoring of plasma glucose was undertaken at 4 occasions every day. Glucose values were used to assess several indices of glycemic control quality, such as glucose mean, GRADE, M-VALUE, hypoglycemia and hyperglycemia index, and indices of glycemic variability, such as standard deviation, CONGA, J-INDEX, and MAGE. We found that vildagliptin improved the glycemic condition compared to placebo: mean glycemic levels, and both GRADE and M-VALUE, were reduced by vildagliptin (P < 0.01). Indices also showed that vildagliptin reduced glycemia without increasing the risk for hypoglycemia. Almost all indices of glycemic variability showed an improvement of the glycemic condition with vildagliptin (P < 0.02), though more marked differences were shown by the more complex indices. In conclusion, the study shows that four-sample preprandial glucose self-monitoring is sufficient to yield information on the vildagliptin effects on glycemic control and variability.

References

  1. Diabetes Obes Metab. 2013 Dec;15(12):1111-9 - PubMed
  2. Diabetes Metab Syndr. 2013 Jan-Mar;7(1):32-4 - PubMed
  3. Diabetes Care. 2006 Nov;29(11):2433-8 - PubMed
  4. Diabetes Res Clin Pract. 2011 Dec;94(3):371-6 - PubMed
  5. Diabetes Ther. 2012 Nov;3(1):11 - PubMed
  6. Diabetes Care. 2000 Jan;23(1):45-50 - PubMed
  7. Diabetes Obes Metab. 2014 Sep;16(9):812-8 - PubMed
  8. Diabetes Technol Ther. 2013 Mar;15(3):237-40 - PubMed
  9. Curr Med Res Opin. 2012 Apr;28(4):513-23 - PubMed
  10. Diabetes Metab. 2012 Oct;38(4):359-66 - PubMed
  11. Diabetes Care. 2011 Aug;34(8):1843-7 - PubMed
  12. Diabetes Care. 2013 Dec;36(12):3875-81 - PubMed
  13. Int J Clin Pract. 2010 Nov;64(12):1705-11 - PubMed
  14. Postgrad Med. 2011 Jul;123(4):107-18 - PubMed
  15. Diabet Med. 2010 Feb;27(2):175-80 - PubMed
  16. Diabetes Technol Ther. 2009 Jun;11 Suppl 1:S55-67 - PubMed
  17. Diabetes Technol Ther. 2011 Jul;13(7):699-703 - PubMed
  18. Cardiovasc Diabetol. 2012 Aug 06;11:92 - PubMed
  19. Diabetes Obes Metab. 2005 Jan;7(1):56-64 - PubMed
  20. Diabetes Obes Metab. 2013 Mar;15(3):252-7 - PubMed
  21. Diabetes Metab. 2008 Dec;34(6 Pt 1):612-6 - PubMed
  22. World J Diabetes. 2014 Feb 15;5(1):40-51 - PubMed
  23. Endocr J. 2013;60(10 ):1207-14 - PubMed
  24. J Diabetes Sci Technol. 2013 May 01;7(3):640-5 - PubMed
  25. Diabetes Care. 1997 Nov;20(11):1655-8 - PubMed
  26. Acta Med Scand. 1965 Jan;177:95-102 - PubMed
  27. J Diabetes Sci Technol. 2009 Jul 01;3(4):649-55 - PubMed
  28. Diabetes Technol Ther. 2011 Jan;13(1):11-7 - PubMed
  29. Vasc Health Risk Manag. 2013;9:57-64 - PubMed
  30. Diabetologia. 2007 Jun;50(6):1148-55 - PubMed
  31. Diabetes. 1970 Sep;19(9):644-55 - PubMed
  32. J Diabetes Complications. 2010 Mar-Apr;24(2):79-83 - PubMed
  33. Diabetes Technol Ther. 2009 Sep;11(9):551-65 - PubMed
  34. Diabetes Res Clin Pract. 2012 Mar;95(3):303-11 - PubMed
  35. Endocr Rev. 2010 Apr;31(2):171-82 - PubMed
  36. Diabet Med. 2007 Jul;24(7):753-8 - PubMed
  37. Diabetes Obes Metab. 2010 Feb;12(2):167-77 - PubMed
  38. Diabetes Res Clin Pract. 2011 Feb;91(2):e40-2 - PubMed

Publication Types